Company intelligence / Profile preview

WIN

Hong Kong, Hong Kong SAR

Ownership: Private
Development stage: Other

Overview

WinHealth Pharma has regulatory approval for prescription drugs in Japan and China and is actively expanding internationally, offering commercialized and pipeline products in cardiovascular, renal, oncology, GI, respiratory, infectious, and rare diseases. The company's successful global expansion was marked by obtaining a Type 1 Drug Manufacturing/Marketing Business License in Japan in 2025, enabling full commercial activities in regulated markets.[2][6]

Therapeutic areas: NephrologyCardiovascularGastroenterologyPulmonologyInfectious DiseasesRare DiseasesHematology
Modalities: Small moleculeBiologic
Industry: Biotech

Beyond the preview

Go deeper on WIN.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WIN.

Explore the full profile